Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more
Voyageur Pharmaceuticals Ltd (VYYRF) - Total Liabilities
Latest total liabilities as of August 2025: $2.23 Million USD
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VYYRF) has total liabilities worth $2.23 Million USD as of August 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Voyageur Pharmaceuticals Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Voyageur Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Voyageur Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kingsmen Creatives Ltd
PINK:KMNCF
|
USA | $158.01 Million |
|
Lian Hong Art. Co., Ltd.
TWO:6755
|
Taiwan | NT$1.95 Billion |
|
AdVini S.A.
PA:ALAVI
|
France | €289.66 Million |
|
LMS Co. Ltd
KQ:073110
|
Korea | ₩81.93 Billion |
|
Saga Pure ASA
OL:SAGA
|
Norway | Nkr4.22 Million |
|
Dish TV India Limited
PINK:DTTVY
|
USA | $57.40 Billion |
|
Health & Life Co., Ltd.
TWO:1781
|
Taiwan | NT$326.71 Million |
|
Delta Resources Ltd
PINK:DTARF
|
USA | $1.25 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Voyageur Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Voyageur Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Voyageur Pharmaceuticals Ltd (2011–2024)
The table below shows the annual total liabilities of Voyageur Pharmaceuticals Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | $2.15 Million | +195.16% |
| 2023-11-30 | $727.88K | +15.38% |
| 2022-11-30 | $630.83K | -4.51% |
| 2021-11-30 | $660.64K | -31.81% |
| 2020-11-30 | $968.85K | +13.62% |
| 2019-11-30 | $852.69K | +13.57% |
| 2018-11-30 | $750.79K | -21.72% |
| 2017-11-30 | $959.12K | +2368.08% |
| 2016-11-30 | $38.86K | +318.67% |
| 2015-11-30 | $9.28K | -88.17% |
| 2014-11-30 | $78.45K | +814.22% |
| 2013-11-30 | $8.58K | -63.44% |
| 2012-11-30 | $23.47K | +10.68% |
| 2011-11-30 | $21.21K | -- |